Search the Newsreel

Delcath Systems (DCTH) adopts new exclusive forum clauses in amended bylaws

Delcath Systems, Inc. (DCTH) has amended its bylaws, effective August 12, 2026, to include exclusive forum provisions for legal disputes. The updated bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for internal corporate claims, and the federal …

Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Zacks Research

Zacks Research has upgraded Delcath Systems (NASDAQ:DCTH) stock from a "hold" to a "strong-buy" rating. This upgrade follows positive earnings results where the company reported $0.07 EPS, significantly beating the estimated loss, and revenue of $29.13 million, exceeding expectations. Other analysts maintain a generally …

Delcath Systems (NASDAQ:DCTH) Hits New 12-Month High - Here's What Happened

Delcath Systems (NASDAQ:DCTH) recently reached a new 52-week high, trading as high as $17.42. The stock experienced positive sentiment from analysts, with HC Wainwright maintaining a "Buy" rating and increasing its price target, and Zacks identifying it as a potential momentum stock. Despite a …

HC Wainwright Boosts Earnings Estimates for Delcath Systems

HC Wainwright has increased its Q3 2026 EPS estimate for Delcath Systems (NASDAQ: DCTH) from a loss of $0.29 to a loss of $0.10, maintaining a "Buy" rating and a $32 price target. This revision follows Delcath's strong Q2 earnings report, where the company …

Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?

Shares of Delcath Systems, Inc. (DCTH) have recently gained 29.5%, and Wall Street analysts project a further potential upside of 42.8%, with a mean target price of $23.8. While analysts' price targets can be overly optimistic, the agreement among analysts on higher earnings estimates …

Delcath Systems resumes post-earnings momentum with 10% rally, sets new high (DCTH:NASDAQ)

Delcath Systems (DCTH) Stock Profit Turn Faces Pricing Pressure

Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Delcath Systems (NASDAQ:DCTH) from a "hold" to a "buy" rating, with other analysts maintaining buy ratings and raising price targets, leading to a consensus "Moderate Buy" rating and an average price target of $23.17. The company recently reported strong quarterly …

Delcath Systems (NASDAQ:DCTH) Issues Earnings Results, Beats Estimates By $0.16 EPS

Delcath Systems (NASDAQ:DCTH) reported stronger-than-expected Q2 earnings, with EPS of $0.07 against an estimated loss of $0.09, and revenue reaching $29.13 million, surpassing expectations. The company raised its full-year 2026 revenue guidance to $104 million-$108 million, driven by a 21% year-over-year increase in HEPZATO …

Delcath Systems Inc (DCTH) Stock News Today

Delcath Systems, Inc. Stock 12‑Month Price Target Raised to $24.17, Implies 91% Upside

Delcath Systems, Inc. (DCTH) has seen its average 12-month price target raised to $24.17 by 6 analysts, up from $22.5, with individual forecasts ranging from $21 to $30. This updated target suggests a potential upside of approximately 91% from its August 5th closing price. …

Earnings call transcript: Delcath jumps on Q2 2026 revenue beat and raised outlook

Delcath Systems reported strong Q2 2026 results, exceeding revenue forecasts with $29.1 million, driven by demand for its HEPZATO KIT for metastatic uveal melanoma. The company raised its full-year 2026 revenue guidance to $104 million-$108 million and saw its shares jump in premarket trading. …

Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research

BTIG Research has raised its price target for Delcath Systems (NASDAQ:DCTH) to $21.00 from $17.00, maintaining a "Buy" rating and implying a 40% upside. This follows Delcath's strong quarterly performance, where it exceeded revenue and EPS expectations. The stock surged 18.8% to $15.00 on …

Delcath Systems Inc (DCTH) Beats Revenue Estimates with $29.1 Million in Q2 Earnings: GF Score 73/100, 66.7% Undervalued

Delcath Systems Inc (DCTH) reported Q2 2026 revenue of $29.1 million, surpassing analyst estimates, driven by strong HEPZATO KIT sales. Despite increased R&D expenses, the oncology company maintained stable net income and improved gross margins. Delcath is well-positioned for future growth with a robust …

Delcath Systems Q2 Earnings Call Highlights

Delcath Systems reported strong Q2 2026 results with a 20% year-over-year revenue increase to $29.1 million, driven by a 30% rise in HEPZATO KIT volume. The company raised its full-year 2026 revenue guidance to $104 million–$108 million and expects positive adjusted EBITDA. Delcath is …

Delcath Systems (NASDAQ:DCTH) Sets New 12-Month High After Better-Than-Expected Earnings

DELCATH SYSTEMS, INC. 1Q 2026: Revenue $29.13M, EPS $0.07— 10-Q Summary

DELCATH SYSTEMS, INC. reported its first-quarter 2026 results, showing revenue of $29.13 million, a 20.6% increase year-over-year, and diluted EPS of $0.07, which was flat compared to the prior year. Net income was $2.67 million, a slight decrease of 1.1%. The revenue growth was …

Delcath's global Phase 2 trial doses first patient in breast cancer

Delcath Systems announced strong second-quarter 2026 financial results, reporting total revenue of $29.1 million and raising its full-year 2026 revenue guidance to between $104 million and $108 million. The company also highlighted the dosing of the first patient in its global Phase 2 trial …

Delcath Systems (NASDAQ: DCTH) posts Q2 profit and builds oncology pipeline

Delcath Systems reported a profitable Q2 2026 with $29.1 million in revenue, driven by increased adoption of its liver cancer therapies, HEPZATO KIT and CHEMOSAT. The company achieved a net income of $2.7 million and is advancing Phase 2 clinical trials for HEPZATO in …

Delcath Systems Q2 2026: Revenue $29.1M, Gross Margin 90%, Raises 2026 Guidance to $104M–$108M

Delcath Systems reported strong Q2 2026 results, with product revenue reaching $29.1 million and gross margin at 90%. The company achieved a net income of $2.7 million and adjusted EBITDA of $7.6 million, largely driven by HEPZATO KIT sales. Consequently, Delcath Systems has raised …

Delcath Q2 2026 Earnings: Revenue Rises While Clinical Spending Pressures EBITDA

Delcath Systems reported a 21% increase in Q2 2026 revenue, reaching $29.1 million, driven primarily by HEPZATO KIT sales. Despite a 90% gross margin and lower cost of goods sold, higher clinical and commercial spending led to a decline in non-GAAP adjusted EBITDA and …

Delcath Systems Inc (DCTH) Earnings Date & Reports & Earnings News

Why (DCTH) Price Action Is Critical for Tactical Trading

This article analyzes Delcath Systems Inc. (NASDAQ: DCTH), highlighting critical price action for tactical trading based on AI models. It notes divergent sentiment across time horizons, indicating potential choppiness but also a breakout underway with compelling upside if sustained. The analysis provides specific trading …

Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview

Delcath Systems Inc is projected to report a loss of 9 cents per share, according to this earnings preview. The article, sourced from Reuters via Refinitiv, provides a brief update on the company's expected financial performance.

Delcath Systems, Inc. Revenue Breakdown – NASDAQ:DCTH

This article details Delcath Systems, Inc.'s revenue breakdown for the last fiscal year. The company generated $85.23 million USD, with its Hepzato Kit segment contributing the majority at $78.83 million USD. The United States was the largest regional contributor, also accounting for $78.83 million …

Delcath Systems Inc (DCTH) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Delcath Systems Inc (DCTH), noting its current valuation score of 4.95 and ranking within the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of 812.96, along with the absence of disclosed data for …

Delcath Systems (DCTH) Projected to Post Quarterly Earnings on Thursday

Delcath Systems Inc (DCTH) Institutional Confidence

The article analyzes Delcath Systems Inc's (DCTH) institutional confidence, noting its current score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. Institutional shareholding decreased by 20.44% quarter-over-quarter, with Bill Nygren | OAKMX being the largest institutional shareholder …

Liver-cancer treatment company Delcath heads to Boston Aug. 11

Delcath Systems, an interventional oncology company specializing in liver cancer treatments, announced that its management will attend the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company focuses on its proprietary products, HEPZATO KIT and CHEMOSAT, which deliver high-dose …

Delcath Systems Inc (DCTH) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Delcath Systems Inc (DCTH) stock performance and dividend history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing, market capitalization, and P/E ratio for DCTH.

DCTH|Delcath Systems Inc|Price:11.960|Chg%:-0.260

This article provides a comprehensive stock analysis of Delcath Systems Inc (DCTH) from TradingKey, highlighting its healthy fundamentals, high growth potential, and "Buy" ratings from analysts with a target price of $22.33. Despite recent weak market performance, the company shows strong fundamentals and is …

Delcath Systems, Inc. Revenue Breakdown – LS:A2PT5P

Delcath Systems, Inc. generated €72.57 million in revenue last year, with its top-performing segment, Hepzato Kit, contributing €67.12 million, a significant increase from €31.20 million in the prior year. All of this top segment's revenue came from the United States. The article provides a …

Press Release: Delcath Systems to Host Second Quarter 2026 Earnings Call

Delcath Systems (NASDAQ: DCTH) announced it will host an earnings call on August 8, 2026, at 8:30 AM ET to discuss its second-quarter 2026 financial results. The call will follow the release of the results after market close on August 7, 2026. Interested parties …